Meropenem Venus Pharma (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins (PBPs) on the bacterial cell wall. This binding blocks the transpeptidation step of peptidoglycan synthesis, weakening the cell wall and causing bacterial lysis and death. Its high affinity for a wide range of PBPs gives it activity against many multidrug‑resistant organisms.

The dosage of Meropenem Venus Pharma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. Dosing regimens are individualized and should follow local guidelines or the prescriber’s judgment; no fixed dose is provided here.

Meropenem is classified as pregnancy category unknown, meaning that safety data are limited. It should be used during pregnancy or lactation only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a healthcare professional is essential before use.

To order Meropenem Venus Pharma, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Meropenem shares the broad‑spectrum activity characteristic of carbapenems but is distinguished by a slightly lower propensity for inducing seizures compared with imipenem. It offers excellent stability against many β‑lactamases and provides reliable coverage for anaerobes, making it a preferred option for intra‑abdominal and mixed infections when resistance is a concern.

Meropenem Venus Pharma, supplied as a powder for solution for injection, must be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking the reconstituted solution. Follow aseptic techniques during preparation and administration.

Meropenem is administered intravenously. The powder is reconstituted with a suitable diluent (usually sterile water or a compatible electrolyte solution) to the recommended concentration, then further diluted in an infusion bag if required. The infusion is given over a period specified by the prescriber, typically 15‑30 minutes, under aseptic conditions.

The most serious adverse events associated with Meropenem include seizures (particularly in patients with renal dysfunction or pre‑existing CNS disorders), severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Clinicians should monitor neurological status, renal function and signs of allergic reactions throughout therapy.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. It should be used with caution, or avoided, in individuals with severe renal impairment unless dose‑adjusted, and in patients with a history of seizures unless the benefits clearly outweigh the risks.